Skip to main content
SpringerLink
Log in

Fungal Infections of the Brain

  • Chapter
  • First Online:
Neurological Complications of Infectious Diseases

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

CNS fungal infections are associated with high morbidity and mortality. The most frequent etiology is cryptococcosis, which causes subacute meningoencephalitis among patients with advanced HIV and solid organ transplant. Diagnosis is based on cerebrospinal fluid (CSF) antigen testing or culture. The treatment of choice is liposomal amphotericin B (LAmB) with 5-flucytosine for 2 weeks, followed by prolonged maintenance with fluconazole. Hematogenous dissemination of invasive candidiasis causes CNS micro abscesses and meningitis. CSF culture is insensitive, the determination of β-D glucan may aid diagnosis. Initial treatment with LAmB and prolonged maintenance with azoles is recommended. CNS involvement in the setting of disseminated histoplasmosis, blastomycosis and coccidioidomycosis occurs among immunocompromised patients living or visiting endemic zones. Diagnosis is difficult, cultures are insensitive, antigen testing or serology aids the diagnosis. CNS invasion in the setting of invasive aspergillosis and mucormycosis may be seen by local invasion or hematogenous dissemination. Early surgical consultation is a priority in addition to antifungal therapy. Dematiaceous fungi are emergent mycosis that may cause healthcare related outbreaks and CNS infection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ko JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. 2015:1–22. https://doi.org/10.1101/cshperspect.a019273.

  2. Raman SR. Fungal infections of the nervous system: current perspective and controversies in management. Int J Surg. 2010;8(8):591–601. https://doi.org/10.1016/j.ijsu.2010.07.293.

    Article  Google Scholar 

  3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America, vol. 36; 2010. https://doi.org/10.3109/10408410903241444.

    Book  Google Scholar 

  4. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165). https://doi.org/10.1126/scitranslmed.3004404.

  5. Góralska K, Blaszkowska J, Dzikowiec M. Neuroinfections caused by fungi. Infection. 2018;46(4):443–59. https://doi.org/10.1007/s15010-018-1152-2.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Liu Y, Mittal R, Solis NV, Prasadarao NV, Filler SG. Mechanisms of candida albicans trafficking to the brain. PLoS Pathog. 2011;7(10). https://doi.org/10.1371/journal.ppat.1002305.

  7. Jong A, Wu CH, Prasadarao NV, et al. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-α activation. Cell Microbiol. 2008;10(9):1854–65. https://doi.org/10.1111/j.1462-5822.2008.01172.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Santiago-Tirado FH, Doering TL. False friends: phagocytes as Trojan horses in microbial brain infections. PLoS Pathog. 2017;13(12):1–7. https://doi.org/10.1371/journal.ppat.1006680.

    Article  CAS  Google Scholar 

  9. Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015;78:16–48. https://doi.org/10.1016/j.fgb.2015.02.009.

    Article  CAS  PubMed  Google Scholar 

  10. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis. 2011;17(2):193–9. https://doi.org/10.3201/eid1702.101020.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Saijo T, Chen J, Chen SC, et al. Autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. MBio. 2014;5(2):1–8. https://doi.org/10.1128/mBio.00912-14.Editor.

    Article  Google Scholar 

  12. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2016;30(1):179–206. https://doi.org/10.1016/j.idc.2015.10.006.

    Article  Google Scholar 

  13. Pappas P. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61–79.

    PubMed  PubMed Central  Google Scholar 

  14. Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis. 2011;53(2):168–76. https://doi.org/10.1093/cid/cir276.

    Article  PubMed  Google Scholar 

  15. Singh N, Lortholary O, Alexander BD, et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation. 2005;80(8):1131–3. https://doi.org/10.1097/01.tp.0000180530.17683.02.

    Article  PubMed  Google Scholar 

  16. Sun HY, Alexander BD, Huprikar S, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis. 2015;60(1):36–44. https://doi.org/10.1093/cid/ciu711.

    Article  PubMed  Google Scholar 

  17. Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen H. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis. 2006;42(in 2):1443–50.

    Article  Google Scholar 

  18. Nalintya E, Kiggundu R, Meya D. Evolution of cryptococcal antigen testing: what is new? Curr Fungal Infect Rep. 2016;10(2):62–7. https://doi.org/10.1007/s12281-016-0256-3.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Neagu MR, Raibagkar P, Lyons JL, Klein JP. Imaging in neurologic infections II: fungal and viral diseases. Curr Infect Dis Rep. 2015;17(4). https://doi.org/10.1007/s11908-015-0474-9.

  20. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322. https://doi.org/10.1086/649858.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004–17. https://doi.org/10.1056/NEJMoa1710922.

    Article  CAS  PubMed  Google Scholar 

  22. Jarvis JN, Leeme TB, Molefi M, et al. Short-course high-dose liposomal amphotericin B for human immunodeficiency virus–associated cryptococcal meningitis: a phase 2 randomized controlled trial. Clin Infect Dis. 2018:1–9. https://doi.org/10.1093/cid/ciy515.

  23. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487–98. https://doi.org/10.1056/NEJMoa1312884.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. World Health Organization. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization. 2018. https://apps.who.int/iris/handle/10665/260399.

  25. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56(4):745–55. https://doi.org/10.1093/jac/dki288.

    Article  CAS  PubMed  Google Scholar 

  26. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–31. https://doi.org/10.1086/374557.

    Article  CAS  PubMed  Google Scholar 

  27. Thompson GR, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63(3):356–62. https://doi.org/10.1093/cid/ciw305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Anekthananon T, Manosuthi W, Chetchotisakd P, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS. 2011;22(11):665–70. https://doi.org/10.1258/ijsa.2011.010538.

    Article  CAS  PubMed  Google Scholar 

  29. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791–802. https://doi.org/10.1016/S1473-3099(10)70170-5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. McCarty TP, Pappas PG. Invasive Candidiasis. Infect Dis Clin N Am. 2016;30(1):103–24. https://doi.org/10.1016/j.idc.2015.10.013.

    Article  Google Scholar 

  31. Sánchez-Portocarrero J, Pérez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000;37(3):169–79. https://doi.org/10.1016/S0732-8893(00)00140-1.

    Article  PubMed  Google Scholar 

  32. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4):e1–e50. https://doi.org/10.1093/cid/civ933.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Parker JC, McCloskey JJ, Lee RS. Human cerebral candidosis – a postmortem evaluation of 19 patients. Hum Pathol. 1981;12(1):23–8. https://doi.org/10.1016/S0046-8177(81)80238-9.

    Article  PubMed  Google Scholar 

  34. Lanternier F, Mahdaviani SA, Barbati E, et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species–induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol. 2015;135(6):1558–1568.e2. https://doi.org/10.1016/j.jaci.2014.12.1930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Aristizabal N, Vagner B. Infections of the central nervous system by Candida. J Infect Dis Immun. 2011;3(5):79–84. https://doi.org/10.1097/00006123-199306000-00035.

    Article  Google Scholar 

  36. Lyons JL, Thakur KT, Lee R, et al. Utility of measuring (1,3)-β-D-Glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection. J Clin Microbiol. 2015;53(1):319–22. https://doi.org/10.1128/JCM.02301-14.

    Article  CAS  PubMed  Google Scholar 

  37. Nakayama H, Shibuya K, Kimura M, Ueda M, Iwabuchi S. Histopathological study of candidal infection in the central nervous system. Jpn J Med Mycol. 2010;51(1):31–45. https://doi.org/10.3314/jjmm.51.31.

    Article  Google Scholar 

  38. O’Brien D, Stevens NT, Lim CH, et al. Candida infection of the central nervous system following neurosurgery: a 12-year review. Acta Neurochir. 2011;153(6):1347–50. https://doi.org/10.1007/s00701-011-0990-9.

    Article  PubMed  Google Scholar 

  39. Gavino C, Cotter A, Lichtenstein D, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. Clin Infect Dis. 2014;59(1):81–4. https://doi.org/10.1093/cid/ciu215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infect Dis Clin N Am. 2016;30(1):207–27. https://doi.org/10.1016/j.idc.2015.10.009.

    Article  Google Scholar 

  41. Wheat J, Myint T, Guo Y, et al. Central nervous system histoplasmosis. Medicine (Baltimore). 2018;97(13):e0245. https://doi.org/10.1097/MD.0000000000010245.

    Article  CAS  Google Scholar 

  42. Schestatsky P, Chedid MF, Amaral OB, Unis G, Oliveira FM, Severo LC. Isolated central nervous system histoplasmosis in immunocompetent hosts: a series of 11 cases. Scand J Infect Dis. 2006;38(1):43–8. https://doi.org/10.1080/00365540500372895.

    Article  PubMed  Google Scholar 

  43. Estrada-Bellmann I, Camara-Lemarroy CR, Flores-Cantu H, Calderon-Hernandez HJ, Villareal-Velazquez HJ. Hemichorea in a patient with HIV-associated central nervous system histoplasmosis. Int J STD AIDS. 2016;27(1):75–7. https://doi.org/10.1177/0956462414564608.

    Article  CAS  PubMed  Google Scholar 

  44. Veeravagu A, Ludwig C, Camara-Quintana JQ, Jiang B, Lad N, Shuer L. Fungal infection of a ventriculoperitoneal shunt: Histoplasmosis diagnosis and treatment. World Neurosurg. 2013;80(1–2):222.e5–222.e13. https://doi.org/10.1016/j.wneu.2012.12.01.

    Article  Google Scholar 

  45. Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis. 2005;40(6):844–52. https://doi.org/10.1086/427880.

    Article  CAS  PubMed  Google Scholar 

  46. Starkey J, Moritani T, Kirby P. MRI of CNS fungal infections: review of aspergillosis to histoplasmosis and everything in between. Clin Neuroradiol. 2014;24(3):217–30. https://doi.org/10.1007/s00062-014-0305-7.

    Article  CAS  PubMed  Google Scholar 

  47. Trofa D, Nosanchuk JD. Histoplasmosis of the central nervous system. J Neuro-Oncol. 2012;3(7):1–7. https://doi.org/10.4303/jnp/235594.

    Article  Google Scholar 

  48. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807–25. https://doi.org/10.1086/521259.

    Article  PubMed  Google Scholar 

  49. Stockamp NW, Thompson GR. Coccidioidomycosis. Infect Dis Clin N Am. 2016;30(1):229–46. https://doi.org/10.1016/j.idc.2015.10.008.

    Article  Google Scholar 

  50. Odio CD, Marciano BE, Galgiani JN, Holland SM. Risk factors for disseminated coccidioidomycosis, United States. Emerg Infect Dis. 2017;23(2):308–11. https://doi.org/10.3201/eid2302.160505.

    Article  CAS  PubMed Central  Google Scholar 

  51. Goldstein EJC, Johnson RH, Einstein HE. Coccidioidal meningitis. Clin Infect Dis. 2006;42(1):103–7. https://doi.org/10.1086/497596.

    Article  Google Scholar 

  52. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124(3):305–10. https://doi.org/10.7326/0003-4819-124-3-199602010-00004.

    Article  CAS  PubMed  Google Scholar 

  53. Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011;53(11):1060–6. https://doi.org/10.1093/cid/cir642.

    Article  CAS  PubMed  Google Scholar 

  54. Castillo CG, Kauffman CA, Miceli MH. Blastomycosis. Infect Dis Clin N Am. 2016;30(1):247–64. https://doi.org/10.1016/j.idc.2015.10.002.

    Article  Google Scholar 

  55. Ho J, Fowler P, Heidari A, Johnson RH. Intrathecal amphotericin B: a 60-year experience in treating coccidioidal meningitis. Clin Infect Dis. 2017;64(4):519–24. https://doi.org/10.1093/cid/ciw794.

    Article  CAS  PubMed  Google Scholar 

  56. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(12):1801–12. https://doi.org/10.1086/588300.

    Article  CAS  PubMed  Google Scholar 

  57. Bariola JR, Perry P, Pappas PG, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis. 2010;50(6):797–804. https://doi.org/10.1086/650579.

    Article  PubMed  Google Scholar 

  58. Monteiro De Almeida S. Central nervous system paracoccidioidomycosis: an overview. Braz J Infect Dis. 2005;9(2):126–33. https://doi.org/10.1590/S1413-86702005000200002.

    Article  Google Scholar 

  59. Le T, Huu Chi N, Kim Cuc NT, et al. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis. 2010;51(12):1458–62. https://doi.org/10.1086/657400.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bonifaz A, Tirado-Sánchez A. Cutaneous disseminated and extracutaneous sporotrichosis: current status of a complex disease. J Fungi. 2017;3(1):6. https://doi.org/10.3390/jof3010006.

    Article  CAS  Google Scholar 

  61. Freitas DFS, Lima MA, De Almeida-Paes R, et al. Sporotrichosis in the central nervous system caused by Sporothrix brasiliensis. Clin Infect Dis. 2015;61(4):663–4. https://doi.org/10.1093/cid/civ361.

    Article  PubMed  Google Scholar 

  62. Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal infection in a US Health Care Network. Open Forum Infect Dis. 2018;5(8):2–9. https://doi.org/10.1093/ofid/ofy187.

    Article  Google Scholar 

  63. Cadena J, Thompson GR, Patterson TF. Invasive aspergillosis: current strategies for diagnosis and management. Infect Dis Clin N Am. 2016;30(1):125–42. https://doi.org/10.1016/j.idc.2015.10.015.

    Article  Google Scholar 

  64. Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2003;31(3):191–6. https://doi.org/10.1038/sj.bmt.1703812.

    Article  CAS  PubMed  Google Scholar 

  65. Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Med (United States). 2012;91(6):328–36. https://doi.org/10.1097/MD.0b013e318274cd77.

    Article  Google Scholar 

  66. Panda PK, Mavidi SK, Wig N, Garg A, Nalwa A, Sharma MC. Intracranial aspergillosis in an immunocompetent young woman. Mycopathologia. 2017;182(5–6):527–38. https://doi.org/10.1007/s11046-016-0106-4.

    Article  PubMed  Google Scholar 

  67. Antinori S, Corbellino M, Meroni L, et al. Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect. 2013;66(3):218–38. https://doi.org/10.1016/j.jinf.2012.11.003.

    Article  PubMed  Google Scholar 

  68. Reinwald M, Buchheidt D, Hummel M, et al. Diagnostic performance of an aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis. PLoS ONE. 2013;8(2):1–6. https://doi.org/10.1371/journal.pone.0056706.

    Article  CAS  Google Scholar 

  69. Panackal AA, Williamson PR. Fungal infections of the central nervous system. Contin Lifelong Learn Neurol. 2015;21(3):1662–78. https://doi.org/10.1212/CON.0000000000000241.

    Article  Google Scholar 

  70. Patterson TF, Thompson GR, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):433–42. https://doi.org/10.1093/cid/ciw444.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Schwartz S. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106(8):2641–5. https://doi.org/10.1182/blood-2005-02-0733.

    Article  CAS  PubMed  Google Scholar 

  72. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore). 2000;79(4):250–60.

    Article  CAS  Google Scholar 

  73. Schwartz S, Reisman A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection. 2011;39(3):201–10. https://doi.org/10.1007/s15010-011-0108-6.

    Article  CAS  PubMed  Google Scholar 

  74. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(suppl 1):23–34. https://doi.org/10.1093/cid/cir866.

    Article  Google Scholar 

  75. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin N Am. 2016;30(1):143–63. https://doi.org/10.1016/j.idc.2015.10.011.

    Article  Google Scholar 

  76. Malik AN, Bi WL, McCray B, Abedalthagafi M, Vaitkevicius H, Dunn IF. Isolated cerebral mucormycosis of the basal ganglia. Clin Neurol Neurosurg. 2014;124(9):102–5. https://doi.org/10.1016/j.clineuro.2014.06.022.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Palacios E, Rojas R, Rodulfa J, González-Toledo E. Magnetic resonance imaging in fungal infections of the brain. Top Magn Reson Imaging. 2014;23(3):199–212. https://doi.org/10.1097/RMR.00000000000000252014.

    Article  PubMed  Google Scholar 

  78. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(S3):5–26. https://doi.org/10.1111/1469-0691.12371.

    Article  CAS  PubMed  Google Scholar 

  79. Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70(11):3116–23. https://doi.org/10.1093/jac/dkv236.

    Article  CAS  PubMed  Google Scholar 

  80. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715–22. https://doi.org/10.1093/jac/dkr375.

    Article  CAS  PubMed  Google Scholar 

  81. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–71. https://doi.org/10.1086/589857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Zuniga MG, Turner JH. Treatment outcomes in acute invasive fungal rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2014;22(3):242–8. https://doi.org/10.1097/MOO.0000000000000048.

    Article  PubMed  Google Scholar 

  83. Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis. 2018:1–10. https://doi.org/10.1093/cid/ciy406.

  84. Vironneau P, Kania R, Morizot G, et al. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. Clin Microbiol Infect. 2014;20(5):O336–9. https://doi.org/10.1111/1469-0691.12408.

    Article  CAS  PubMed  Google Scholar 

  85. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24. https://doi.org/10.1182/blood-2011-03-316430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J. 2004;80(949):670–4. https://doi.org/10.1136/pgmj.2003.016030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Chowdhary A, Meis JF, Guarro J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20(S3):47–75. https://doi.org/10.1111/1469-0691.12515.

    Article  CAS  PubMed  Google Scholar 

  88. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis. 2004;38(2):206–16. https://doi.org/10.1086/380635.

    Article  PubMed  Google Scholar 

  89. Kantarcioglu AS, Guarro J, De Hoog S, Apaydin H, Kiraz N. An updated comprehensive systematic review of Cladophialophora bantiana and analysis of epidemiology, clinical characteristics, and outcome of cerebral cases. Med Mycol. 2017;55(6):579–604. https://doi.org/10.1093/mmy/myw124.

    Article  PubMed  Google Scholar 

  90. Filizzola MJ, Martinez F, Rauf SJ. Phaeohyphomycosis of the central nervous system in immunocompetent hosts: report of a case and review of the literature. Int J Infect Dis. 2003;7(4):282–6. https://doi.org/10.1016/S1201-9712(03)90108-1.

    Article  PubMed  Google Scholar 

  91. Larone DH, Walsh TJ. Exserohilum rostratum: anatomy of a national outbreak of fungal meningitis. Clin Microbiol Newsl. 2013;35(23):185–93. https://doi.org/10.1016/j.clinmicnews.2013.11.001.

    Article  Google Scholar 

  92. Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev. 2010;23(4):884–928. https://doi.org/10.1128/CMR.00019-10.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Katragkou A, Pana ZD, Perlin DS, Kontoyiannis DP, Walsh TJ, Roilides E. Exserohilum infections: review of 48 cases before the 2012 United States outbreak. Med Mycol. 2014;52(4):376–86. https://doi.org/10.1093/mmy/myt030.

    Article  CAS  PubMed  Google Scholar 

  94. Schwartz IS, Wiederhold NP, Hanson KE, Patterson TF, Sigler L. Blastomyces helicus, a new dimorphic fungus causing fatal pulmonary and systemic disease in humans and animals in Western Canada and the United States. Clin Infect Dis. 2018:1–8. https://doi.org/10.1093/cid/ciy483.

  95. Stott KE, Hope W. Pharmacokinetics–pharmacodynamics of antifungal agents in the central nervous system. Expert Opin Drug Metab Toxicol. 2018;14(8):803–15. https://doi.org/10.1080/17425255.2018.1492551.

    Article  CAS  PubMed  Google Scholar 

  96. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68–88. https://doi.org/10.1128/CMR.00046-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico City, Mexico

    Maria Fernanda Gonzalez-Lara & Luis Ostrosky-Zeichner

  2. McGovern Medical School, Division of Infectious Diseases, University of Texas, Houston Health Science Center, Memorial Hermann Hospital, Texas Medical Center, Houston, TX, USA

    Luis Ostrosky-Zeichner

Authors
  1. Maria Fernanda Gonzalez-Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis Ostrosky-Zeichner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Fernanda Gonzalez-Lara .

Editor information

Editors and Affiliations

  1. UT Health McGovern Medical School, Houston, TX, USA

    Rodrigo Hasbun, MD MPH

  2. Div of Infectious Dis, MCN A-2200, Vanderbilt University, Nashville, TN, USA

    Karen C. Bloch, MD MPH

  3. Dept of Infectious Diseases, Apt 635, Cleveland Clinic Foundation, Cleveland, OH, USA

    Adarsh Bhimraj, MD

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gonzalez-Lara, M.F., Ostrosky-Zeichner, L. (2021). Fungal Infections of the Brain. In: Hasbun, MD MPH, R., Bloch, MD MPH, K.C., Bhimraj, MD, A. (eds) Neurological Complications of Infectious Diseases. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-030-56084-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56084-3_10

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-56083-6

  • Online ISBN: 978-3-030-56084-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation